TWI675833B - 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑 - Google Patents

布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑 Download PDF

Info

Publication number
TWI675833B
TWI675833B TW106124589A TW106124589A TWI675833B TW I675833 B TWI675833 B TW I675833B TW 106124589 A TW106124589 A TW 106124589A TW 106124589 A TW106124589 A TW 106124589A TW I675833 B TWI675833 B TW I675833B
Authority
TW
Taiwan
Prior art keywords
methyl
amino
pyrimidin
butyl
pyrazol
Prior art date
Application number
TW106124589A
Other languages
English (en)
Chinese (zh)
Other versions
TW201811772A (zh
Inventor
布萊恩Ｔ 哈柏金
Brian T. Hopkins
馬斌
Bin Ma
提摩西 雷門 查
Timothy Raymond CHAN
立宏 孫
Lihong Sun
磊 張
Lei Zhang
葛納珊巴登 庫瑪拉佛
Gnanasambandam Kumaravel
喬瑟夫Ｐ 萊多斯
Joseph P. Lyssikatos
凱文 科奇
Kevin Koch
華 苗
Hua Miao
Original Assignee
美商百健Ｍａ公司
Biogen Ma Inc.
美商桑西斯醫藥公司
Sunesis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ｍａ公司, Biogen Ma Inc., 美商桑西斯醫藥公司, Sunesis Pharmaceuticals, Inc. filed Critical 美商百健Ｍａ公司
Publication of TW201811772A publication Critical patent/TW201811772A/zh
Application granted granted Critical
Publication of TWI675833B publication Critical patent/TWI675833B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW106124589A 2013-12-11 2014-12-11 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑 TWI675833B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914886P 2013-12-11 2013-12-11
US61/914,886 2013-12-11

Publications (2)

Publication Number Publication Date
TW201811772A TW201811772A (zh) 2018-04-01
TWI675833B true TWI675833B (zh) 2019-11-01

Family

ID=52302344

Family Applications (3)

Application Number Title Priority Date Filing Date
TW108127236A TWI744672B (zh) 2013-12-11 2014-12-11 布魯頓氏(bruton's)酪胺酸激酶之聯芳基抑制劑
TW103143378A TWI608002B (zh) 2013-12-11 2014-12-11 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑
TW106124589A TWI675833B (zh) 2013-12-11 2014-12-11 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW108127236A TWI744672B (zh) 2013-12-11 2014-12-11 布魯頓氏(bruton's)酪胺酸激酶之聯芳基抑制劑
TW103143378A TWI608002B (zh) 2013-12-11 2014-12-11 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑

Country Status (32)

Country Link
US (4) US9809577B2 (enExample)
EP (3) EP3872075A1 (enExample)
JP (4) JP6431914B2 (enExample)
KR (1) KR102413253B1 (enExample)
CN (3) CN106459002B (enExample)
AR (2) AR098721A1 (enExample)
AU (2) AU2014362231B2 (enExample)
BR (1) BR112016012860A2 (enExample)
CA (1) CA2932608C (enExample)
CL (2) CL2016001435A1 (enExample)
CY (1) CY1120517T1 (enExample)
DK (1) DK3080103T3 (enExample)
EA (2) EA037942B1 (enExample)
ES (1) ES2678021T3 (enExample)
HR (1) HRP20181109T1 (enExample)
HU (1) HUE040346T2 (enExample)
IL (2) IL246031B (enExample)
LT (1) LT3080103T (enExample)
MX (2) MX388978B (enExample)
MY (1) MY179781A (enExample)
NZ (1) NZ721217A (enExample)
PH (1) PH12016501107B1 (enExample)
PL (1) PL3080103T3 (enExample)
PT (1) PT3080103T (enExample)
RS (1) RS57662B1 (enExample)
SA (1) SA518391170B1 (enExample)
SG (2) SG11201604595VA (enExample)
SI (1) SI3080103T1 (enExample)
SM (1) SMT201800373T1 (enExample)
TW (3) TWI744672B (enExample)
WO (1) WO2015089337A1 (enExample)
ZA (1) ZA201706244B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
PT3080103T (pt) 2013-12-11 2018-07-23 Sunesis Pharmaceuticals Inc Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
JP2018521029A (ja) * 2015-06-10 2018-08-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ブルトン型チロシンキナーゼのビアリール阻害剤のアジピン酸塩形態及び組成物
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
US10821104B2 (en) * 2015-12-07 2020-11-03 Suzhou Sinovent Pharmaceuticals Co., Ltd. Five-membered heterocyclic amides WNT pathway inhibitor
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
CN109477073B (zh) * 2016-03-31 2024-04-12 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
US10710993B2 (en) 2016-06-27 2020-07-14 Hangzhou REX Pharmaceutical Co., LTD. Benzofuran pyrazole amine kinase inhibitor
WO2018017153A1 (en) 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
EP3737677B1 (en) 2018-01-10 2021-11-03 Allinky Biopharma Tetrahydroisoquinoline compounds
CA3252332A1 (en) 2018-01-19 2025-06-04 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
TW202016097A (zh) 2018-05-14 2020-05-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶之抑制劑
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020005888A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
KR102612513B1 (ko) 2018-07-31 2023-12-12 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
MA53914A (fr) * 2018-10-15 2021-08-25 Biogen Ma Inc Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
JP7747523B2 (ja) * 2019-05-15 2025-10-01 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
WO2021133894A1 (en) * 2019-12-23 2021-07-01 Biogen Ma Inc. Btk inhibitors
EP4192587A1 (en) 2020-08-07 2023-06-14 Biogen MA Inc. Btk inhibitors
CN116917279A (zh) * 2020-08-07 2023-10-20 渤健马萨诸塞州股份有限公司 Btk抑制剂
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
MX2024000082A (es) * 2021-06-21 2024-03-05 Beigene Switzerland Gmbh Ligandos de crbn con (r)-glutarimida y métodos de uso.
IL313509A (en) * 2021-12-30 2024-08-01 Beigene Switzerland Gmbh Reduction of proton tyrosine kinase (btk) by fusing btk inhibitors with an e3 ligase ligand and methods of use
CN116891437B (zh) * 2022-04-06 2025-10-28 长春金赛药业有限责任公司 氨基酸衍生物、药物组合物及其制备方法和应用
KR20250127267A (ko) 2023-01-04 2025-08-26 에이비 사이언스 튜불린 중합 억제제
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
IL154240A0 (en) * 2000-08-08 2003-07-31 Ortho Mcneil Pharm Inc 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1713775A4 (en) * 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
PL1951684T3 (pl) * 2005-11-01 2017-03-31 Targegen, Inc. Biarylowe meta-pirymidynowe inhibitory kinaz
UA109412C2 (uk) * 2005-11-01 2015-08-25 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки
EA200870217A1 (ru) * 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
DK2078007T3 (da) * 2006-11-01 2011-12-12 Chroma Therapeutics Ltd Ikk-beta-serin-threonin-proteinkinasehæmmere
US8188272B2 (en) 2007-03-21 2012-05-29 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
JP5479346B2 (ja) * 2007-10-05 2014-04-23 ベラステム・インコーポレーテッド ピリミジン置換プリン誘導体
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CA2815330A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
WO2012133310A1 (ja) 2011-03-31 2012-10-04 美津濃株式会社 アイアンゴルフクラブヘッドおよびアイアンゴルフクラブ
AU2012242777A1 (en) 2011-04-12 2013-10-31 Alzheimer's Institute Of America, Inc. Compositions and therapeutic uses of IKK-related kinase epsilon and TANKbinding kinase 1 inhibitors
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
ES2713196T3 (es) 2013-12-11 2019-05-20 Biogen Ma Inc Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
PT3080103T (pt) * 2013-12-11 2018-07-23 Sunesis Pharmaceuticals Inc Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
WO2015187089A1 (en) * 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
CA2960401C (en) * 2014-10-06 2022-07-26 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.

Also Published As

Publication number Publication date
MY179781A (en) 2020-11-13
SI3080103T1 (sl) 2018-11-30
TW201536765A (zh) 2015-10-01
JP7076022B2 (ja) 2022-05-26
AU2014362231B2 (en) 2019-04-04
CA2932608A1 (en) 2015-06-18
JP2021091733A (ja) 2021-06-17
PH12016501107A1 (en) 2016-07-11
SG10201908558WA (en) 2019-10-30
CL2017001459A1 (es) 2018-03-23
JP2018035201A (ja) 2018-03-08
SG11201604595VA (en) 2016-07-28
TWI744672B (zh) 2021-11-01
JP6526167B2 (ja) 2019-06-05
EP3872075A1 (en) 2021-09-01
JP2016539996A (ja) 2016-12-22
SA518391170B1 (ar) 2022-08-25
EP3357921A2 (en) 2018-08-08
KR20160106072A (ko) 2016-09-09
EP3357921A3 (en) 2018-09-12
CA2932608C (en) 2023-02-14
AU2014362231A1 (en) 2016-07-07
US20220332705A1 (en) 2022-10-20
BR112016012860A2 (pt) 2017-08-08
TWI608002B (zh) 2017-12-11
AR098721A1 (es) 2016-06-08
LT3080103T (lt) 2018-08-10
US20160311802A1 (en) 2016-10-27
ZA201706244B (en) 2019-04-24
DK3080103T3 (en) 2018-07-30
MX388978B (es) 2025-03-20
PT3080103T (pt) 2018-07-23
JP6431914B2 (ja) 2018-11-28
NZ721217A (en) 2021-12-24
PH12016501107B1 (en) 2021-07-21
MX2016007611A (es) 2016-09-09
CN109096274B (zh) 2022-07-01
EA037942B1 (ru) 2021-06-10
CN108947913A (zh) 2018-12-07
CL2016001435A1 (es) 2017-06-09
US11572356B2 (en) 2023-02-07
AU2019201997A1 (en) 2019-04-18
US10759783B2 (en) 2020-09-01
MX370103B (es) 2019-12-02
PL3080103T3 (pl) 2018-10-31
US20180093973A1 (en) 2018-04-05
EP3080103B9 (en) 2018-09-19
EP3080103B1 (en) 2018-04-18
EA201792348A1 (ru) 2018-09-28
SMT201800373T1 (it) 2018-09-13
WO2015089337A1 (en) 2015-06-18
ES2678021T3 (es) 2018-08-08
IL269569B (en) 2021-03-25
EP3080103A1 (en) 2016-10-19
CN106459002A (zh) 2017-02-22
TW201811772A (zh) 2018-04-01
AU2019201997B2 (en) 2020-09-17
JP2019163280A (ja) 2019-09-26
IL246031A0 (en) 2016-08-02
MX2019014228A (es) 2020-01-23
TW202017931A (zh) 2020-05-16
US9809577B2 (en) 2017-11-07
KR102413253B1 (ko) 2022-06-27
EA201691114A1 (ru) 2016-11-30
IL269569A (en) 2019-11-28
IL246031B (en) 2019-10-31
AR110381A2 (es) 2019-03-20
EA030538B1 (ru) 2018-08-31
RS57662B1 (sr) 2018-11-30
CN109096274A (zh) 2018-12-28
HRP20181109T1 (hr) 2018-11-02
HUE040346T2 (hu) 2019-03-28
CY1120517T1 (el) 2019-07-10
US10081619B2 (en) 2018-09-25
CN106459002B (zh) 2018-08-21
AU2019201997C1 (en) 2021-03-18
US20190218204A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
TWI675833B (zh) 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑
CN105732636B (zh) 杂芳化合物及其在药物中的应用
WO2023138583A1 (zh) 杂环类化合物、药物组合物及其应用
EP3398947B1 (en) Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof
JP2020537671A (ja) ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用
TW202500142A (zh) 化合物
HK40058075A (en) Intermediates and processes for the preparation of biaryl compounds
HK40001576A (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK1229333A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK1229333B (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology